S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:CING

Cingulate - CING Stock Forecast, Price & News

$0.98
-0.04 (-3.90%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.98
$1.06
50-Day Range
$0.91
$1.85
52-Week Range
$0.66
$2.04
Volume
53,730 shs
Average Volume
435,590 shs
Market Capitalization
$11.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CING stock logo

About Cingulate (NASDAQ:CING) Stock

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

CING Stock News Headlines

What To Do With Your Trades Today
There’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts pixel
Cingulate Shares Slide 19% on Stock Offering
What To Do With Your Trades Today
There’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts pixel
Why Cingulate Shares Are Trading Higher Today
What Is the Default Mode Network?
Cingulate Pops after Positive Topline Data
Why Is Cingulate (CING) Stock Up 72% Today?
See More Headlines
Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

CING Company Calendar

Today
4/01/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CING
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
$-17,680,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.34 per share

Miscellaneous

Free Float
7,772,000
Market Cap
$11.14 million
Optionable
Not Optionable
Beta
0.06

Key Executives

  • Dr. Shane J. Schaffer Pharm.D. (Age 48)
    PharmD, CEO & Chairman
    Comp: $475k
  • Mr. Louis G. Van Horn CPA (Age 64)
    M.B.A., Exec. VP & CFO
    Comp: $380k
  • Dr. Laurie A. Myers M.B.A. (Age 66)
    Ph.D., Exec. VP & COO
    Comp: $400k
  • Mr. Craig S. Gilgallon Esq. (Age 50)
    Exec. VP, Gen. Counsel & Board Sec.
    Comp: $380k
  • Dr. Raul R. Silva M.D. (Age 65)
    Exec. VP & Chief Science Officer
  • Thomas Dalton
    Head of Investor & PR
  • Dr. Matthew N. Brams M.D. (Age 59)
    Exec. VP & Chief Medical Officer













CING Stock - Frequently Asked Questions

Should I buy or sell Cingulate stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CING shares.
View CING analyst ratings
or view top-rated stocks.

How have CING shares performed in 2023?

Cingulate's stock was trading at $1.00 at the beginning of the year. Since then, CING shares have decreased by 1.5% and is now trading at $0.9850.
View the best growth stocks for 2023 here
.

Are investors shorting Cingulate?

Cingulate saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 404,000 shares, a decline of 62.2% from the February 28th total of 1,070,000 shares. Based on an average daily volume of 848,400 shares, the days-to-cover ratio is presently 0.5 days. Currently, 5.3% of the shares of the company are sold short.
View Cingulate's Short Interest
.

When is Cingulate's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our CING earnings forecast
.

When did Cingulate IPO?

(CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share.

What is Cingulate's stock symbol?

Cingulate trades on the NASDAQ under the ticker symbol "CING."

How do I buy shares of Cingulate?

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cingulate's stock price today?

One share of CING stock can currently be purchased for approximately $0.99.

How much money does Cingulate make?

Cingulate (NASDAQ:CING) has a market capitalization of $11.14 million. The company earns $-17,680,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.

How can I contact Cingulate?

The official website for the company is www.cingulate.com. The company can be reached via phone at 913-942-2300 or via email at ir@cingulate.com.

This page (NASDAQ:CING) was last updated on 4/1/2023 by MarketBeat.com Staff